These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 20888873

  • 21. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 22. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children.
    Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Sawata H, Nakura N, Jaeger RK, Lattanzi M.
    Adv Ther; 2010 Jul 17; 27(7):444-57. PubMed ID: 20586002
    [Abstract] [Full Text] [Related]

  • 23. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.
    Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N.
    Int J Clin Pract; 2010 Mar 17; 64(4):432-8. PubMed ID: 20039974
    [Abstract] [Full Text] [Related]

  • 24. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ.
    J Med Virol; 2013 Sep 17; 85(9):1591-7. PubMed ID: 23852684
    [Abstract] [Full Text] [Related]

  • 25. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun 17; 29(6):548-51. PubMed ID: 19040034
    [Abstract] [Full Text] [Related]

  • 26. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ.
    Vaccine; 2010 Aug 31; 28(38):6221-7. PubMed ID: 20638454
    [Abstract] [Full Text] [Related]

  • 27. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
    Precioso AR, Miraglia JL, Campos LM, Goulart AC, Timenetsky Mdo C, Cardoso MR, Luna E, Mondini G, Guedes Jda S, Raw I.
    Vaccine; 2011 Nov 08; 29(48):8974-81. PubMed ID: 21945258
    [Abstract] [Full Text] [Related]

  • 28. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis.
    Alghisi F, Palma P, Montemitro E, Bernardi S, Pontrelli G, Rossi P, Lucidi V.
    Thorax; 2011 Mar 08; 66(3):259-60. PubMed ID: 21228426
    [No Abstract] [Full Text] [Related]

  • 29. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B, Neri M, Lepri E, Iorio AM.
    Vaccine; 2009 Jun 24; 27(31):4099-103. PubMed ID: 19410623
    [Abstract] [Full Text] [Related]

  • 30. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.
    Sci Transl Med; 2010 Jan 20; 2(15):15ra5. PubMed ID: 20371470
    [Abstract] [Full Text] [Related]

  • 31. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
    Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK.
    Vaccine; 2014 Sep 03; 32(39):5027-34. PubMed ID: 25045825
    [Abstract] [Full Text] [Related]

  • 32. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.
    Vaccine; 2008 Jul 04; 26(29-30):3640-6. PubMed ID: 18514980
    [Abstract] [Full Text] [Related]

  • 33. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.
    Reynales H, Astudillo P, de Vallière S, Hatz C, Schlagenhauf P, Rath B, Velentgas P, Fariña A, Sales-Carmona V, Groth N.
    Vaccine; 2012 Oct 05; 30(45):6436-43. PubMed ID: 22902681
    [Abstract] [Full Text] [Related]

  • 34. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome.
    Esposito S, Selicorni A, Daleno C, Valzano A, Cerutti M, Galeone C, Consolo S, Menni F, Principi N.
    Hum Vaccin; 2011 Jun 05; 7(6):613-7. PubMed ID: 21508673
    [Abstract] [Full Text] [Related]

  • 35. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
    Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ.
    Clin Vaccine Immunol; 2014 Jul 05; 21(7):989-96. PubMed ID: 24828092
    [Abstract] [Full Text] [Related]

  • 36. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.
    Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, Pellicciotta G, Monti A, Mascagni P, Moro M, Vicenzi E.
    AIDS; 2011 Jan 14; 25(2):177-83. PubMed ID: 21150561
    [Abstract] [Full Text] [Related]

  • 37. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.
    Vaccine; 2010 Jan 08; 28(3):840-8. PubMed ID: 19835829
    [Abstract] [Full Text] [Related]

  • 38. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.
    Pediatrics; 2011 May 08; 127(5):e1161-8. PubMed ID: 21464195
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients.
    Son J, Lee SB, Lee DW, Kim IY, Lee SJ, Lee SM, Song SH, Seong EY, Kwak IS.
    Clin Exp Nephrol; 2013 Apr 08; 17(2):275-83. PubMed ID: 22990301
    [Abstract] [Full Text] [Related]

  • 40. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR, Colberg K, Frick M, Preusche A.
    Infection; 2004 Aug 08; 32(4):191-8. PubMed ID: 15293073
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.